Nippon Shinyaku
Nippon Shinyaku Head Office Exterior - Nishioji Street | |
| Company type | Public (K.K)[1][2] |
|---|---|
| Industry | Pharmaceuticals, Functional Foods[1][2][3] |
| Founded | October 1, 1919 in Kyoto, Japan[2] |
| Headquarters | , |
Area served | Worldwide[1][2][3] |
Key people | Toru Nakai (President), Shigenobu Maekawa (Chairman), Takashi Takaya (Director), Kazuchika Takagaki (Director, Head R&D) [2][6][7][8] |
| Products | Prescription drugs, functional foods[1][2] |
Number of employees | 2,243[2][4][5] (2025[2][5]) |
| Website | www |
Nippon Shinyaku Co., Ltd. is a Japanese pharmaceutical company headquartered in Kyoto that develops, manufactures, and markets prescription drugs and functional foods. Founded in 1911, the company initially focused on herbal medicines before expanding into modern pharmaceuticals, with current therapeutic areas including urology, hematology, intractable and rare diseases, and gynecology.[6] Nippon Shinyaku is listed on the Tokyo Stock Exchange and has developed treatments such as viltolarsen for Duchenne muscular dystrophy.[7]
References
- ^ a b c d e f g "Nippon Shinyaku Co Ltd (NPPNY) Company Profile". Stock Analysis. Retrieved 13 September 2025.
- ^ a b c d e f g h i j "Company Profile". Nippon Shinyaku. Retrieved 13 September 2025.
- ^ a b "Nippon Shinyaku Co., Ltd. Company Profile". MarketScreener. Retrieved 13 September 2025.
- ^ a b c "Nippon Shinyaku Co Ltd Company Profile". Financial Times. Retrieved 13 September 2025.
- ^ a b "Nippon Shinyaku Co Ltd (4516.T) Employees". Stock Analysis. Retrieved 13 September 2025.
- ^ Yamaura T (March 2011). "[History of the Nippon Shinyaku Institute for Botanical Research]". Yakugaku Zasshi: Journal of the Pharmaceutical Society of Japan (in Japanese). 131 (3): 395–400. doi:10.1248/yakushi.131.395. PMID 21372535.
- ^ Dhillon S (July 2020). "Viltolarsen: First Approval". Drugs. 80 (10): 1027–1031. doi:10.1007/s40265-020-01339-3. PMID 32519222.